pharmaceut ep downgrad unit state go sg websit
stronger despit fy guidanc cut/gradu recoveri flag
nc chang
upsid tp
yesterday statement flag pharma consum benefit
higher demand driven expect pressur weigh
cut fy guidanc due delay surgic procedur med-tech
compani anticip recoveri expect sale earn
bounc back busi remain fundament strong
 better divis perform well despit coronaviru crisi
help pharma consum med-tech impact
group sale consensu growth like like
pharmaceut sale total group lfl got boost new product
perform still-robust matur portfolio stelara benefit
crohn diseas line extens slower eros lead histor franchis
remicad group sale sale xarelto cardio medic drug
partner bayer us line due neg price benefit
wholesal stock due crisi mainli imbruvica stelara xarelto hiv
pah medic devic divis total group sale declin lfl notabl
surgic procedur delay due coronaviru crisi
hand consum busi total group benefit higher
demand mainli over-the-counter thank coronaviru non-gaap ep dilut
consensu help lower tax rate
lower estim cut fy guidanc reflect coronaviru crisi recoveri
accord compani group sale vs
midpoint adjust ep
mid-teen cut midpoint consensu alreadi cautiou
initi guidanc potenti cut midpoint new
guidanc adjust estim reflect new environ expect
acceler growth notabl med-tech due delay procedur
compani updat coronaviru vaccin one lead two back-up
readi earli compani start build manufactur capac
unit distribut vaccin non-profit capac
hold reiter trade premium vs pharma sector price-to-earnings
justifi good visibl three busi offer given patent expiri
stronger competit histor franchis despit new product launch
diversif life-cycl manag expect earn grow organ
period vs pharma sector
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
simplifi select products/divis
like like
valu minor
valu financi invest
depreci amortis
share basic year end/outstand
share price average hist yr current
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet apr cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
deriv target price sotp averag ev/ebita larg pharma multipl premium consum
med-tech pharma dcf lt growth lt ebita margin wacc
downsid risk slow portfolio rejuven like lead slowdown absenc acquisit patent expiri xarelto
neurosci product weigh growth
upsid risk cancer product darzalex imbruvica other stelara immune-inflamm help off-set gradual
eros tail product midterm
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
report contain contribut research team esg numer rate highest score base
four step rate methodolog includ identifi materi esg factor associ weight sector ii provid key
perform indic compani evalu iii calcul quantit esg rate base sustainalyt data combin sg equiti
esg rate identifi top pick esg rate group three equal tier tier tier contain compani
highest esg numer score esg numer rate consid fundament rate kind complet
separ sg equiti credit rate
sg partner sustainalyt independ provid esg data research support servic gather esg data use
public sustainalyt affili sg sg warrant complet accuraci sustainalyt analysi data
